A Randomized, Open-label, Multi-center, Controlled Phase Ⅲ Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating Hormone rhTSH for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer
Latest Information Update: 26 Oct 2023
At a glance
- Drugs Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary) ; Iodine radioactive
- Indications Carcinoma; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 20 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 20 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 28 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.